Inflammatory Diseases
Pharmacist-Led Program Improves Outcomes In Inflammatory Disease
Embedding specialty pharmacists into patient management for inflammatory diseases significantly improved ...
JANUARY 26, 2026
Patients Show Strong Preference for New Subcutaneous Ocrelizumab Formulation: UVA Study
The recently approved Ocrevus Zunovo subcutaneous formulation of the multiple sclerosis drug ocrelizumab is ...
JANUARY 23, 2026
Caring for Pediatric Patients With Difficult-to-Treat IBD
Pediatric IBD treatment requires balancing off-label therapies, growth concerns, and shared decision-making to ...
NOVEMBER 21, 2025
Subcutaneous Infliximab Found Effective With or Without an Immunosuppressant
Patients who achieved a clinical response to subcutaneous infliximab showed no meaningful differences in outcomes ...
APRIL 28, 2025
Adalimumab Biosimilars: Distinguishing Among the 10
10 biosimilars for adalimumab have been approved and marketed to date, and all share the same indications of the ...
MARCH 15, 2025
Basics and Benefits of Biosimilars: A Rheumatologist’s Take
The use of biosimilars can improve patient access and reduce healthcare costs, but understanding some basic ...
FEBRUARY 13, 2025
SP Pharmacist–Led ED Program Boosts Hepatitis C Treatment
An emergency department-focused, specialty pharmacist–led program for managing HCV at the University of ...
NOVEMBER 20, 2024
Taking the RA Threat to Heart During Pregnancy
Obesity, gestational diabetes mellitus and acute cardiovascular complications are more common among pregnant women ...
NOVEMBER 20, 2024
FDA Approves Fasenra for EGPA
The FDA approved Fasenra for adults with eosinophilic granulomatosis with polyangiitis.
SEPTEMBER 19, 2024
Malnutrition Is Endemic to IBD, but Can Be Managed
Correcting the harms of malnutrition in inflammatory bowel disease often leads to better response to biologic ...
JULY 27, 2024
Postoperative Considerations in IBD
This month, we look at two examples of how to manage postoperative inflammatory bowel disease.
MARCH 25, 2024
Advanced Therapies for IBD Do Not Appear To Raise Thrombotic Risk
In patients with IBD, neither biologics nor small molecule targeted therapies increase the risk for major adverse ...
JANUARY 1, 2024
